Douglas Doerfler discussing Interim Results, 6 Months to 30 June 2016
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATION S PROMULGATED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.
MaxCyte, Inc (AIM: MXCT) is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology.
The Company’s patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.
MaxCyte’s high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company’s cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte’s customers with an established regulatory path.
MaxCyte is also developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies in a number of cancer indications, including solid tumors.
Stark Thompson, PhD (NEC)
Previously CEO Life Technologies, growing it to become the leading developer & manufacturer of products & services for life science research.
Doug Doerfler (CEO)
30 yrs in development & commercialisation of biotech products. Founded MaxCyte in 1998.
Ron Holtz (CFO)
Joined in 2005 after serving as CFO of both public & private companies, including RWD Technologies.
Will Brooke (NED)
Co-Founder & Director of Harbert Management Corporation which has approx $4bn under management.
Stan Erck (NED)
25 yrs in Healthcare & Biotech, and has negotiated substantial deals with major pharmaceuticals. Currently CEO of Novavax Corporation.